Yes it is mrblu,
The numbers associated with these early stage (prec-clin and Stage 1) deals is also encouraging.
The iNKT deals are good - particularly the Gilead/Kite collaboration with Appia. Appia wasn't too different to ALA before their company making deal.
I do notice that the iNKT deals were a couple of years ago and everything since has been T cell therapy based. But there are far more companies in the T-cell (and NK cell) therapies than iNKT.
Little pop in SP over the past couple of weeks has been good .
Yes it is mrblu, The numbers associated with these early stage...
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $173.5M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $70.85K | 419.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 443420 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 238634 | 5 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| ALA (ASX) Chart |